// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Implementation of a new digital exercise tool in axial spondyloarthritis and a musculoskeletal therapy outpatient department: a service evaluation

Jacqui Tomkins - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Axial spondyloarthritis

N/A

A dedicated short MRI protocol for assessing synovitis: evaluating patient acceptability and rheumatologist perceptions

Natasha Thorley - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Infective complications in patients with secondary haemophagocytic lymphohistiocytosis: a case series from a large central London teaching hospital

Pratyasha Saha - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Hemophagocytic lymphohistiocytosis

N/A

Using novel remote electronic monitoring to measure and manage the Rheumatology Clinic backlog generated by COVID-19

Dominik Kurzeja - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Automating blood monitoring and handover for patients with rheumatic diseases commencing disease-modifying anti-rheumatic drugs (DMARDs)

Maria Mirza - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Hydroxychloroquine-related adverse events, attrition and reasons for cessation over 5 years at a district general hospital: estimating future ophthalmology screening service use

Dalal Barahman - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Hydroxychloroquine

Navigating giant cell arteritis (GCA) service during and post COVID-19 pandemic: an audit of GCA care at North Bristol NHS Trust against the BSR quality standards

Kian Wah Lim - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Giant cell arteritis

N/A

Real world experience of switching to an adalimumab biosimilar; different outcomes for axial spondylitis, psoriatic and rheumatoid arthritis

Francesca A A Holden - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Rheumatoid arthritis

Adalimumab biosimilar

Rituximab and COVID-19 vaccines; are they fit for purpose?

Sarah K Stewart - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

Rituximab

Using the BSR Lupus audit as a springboard to improve management of SLE in the outpatient clinic

Rosalind M Benson - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Autoimmune (AI)

Lupus

N/A

A three-year audit of dose tapering biologic medications in a rheumatology service

Helen Light - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Dermatology

Psoriasis

Hydroxyzine

Experience of baricitinib in a real-world population with efficacy and side effects: a South London regional analysis

Olivia Buckeldee - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Baricitinib

Rheumatology advice lines: how to manage rising demand and limited capacity?

Samantha Hider - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

To rescreen or not to rescreen, that is the question: an evaluation of practice of rescreening for infections when switching advanced therapies in rheumatology patients

Ammara Masood - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Hepatitis B

N/A

Prescription trends and reasons for discontinuation amongst at-home biological therapies

Mark D J Gibson - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

Certolizumab pegol

Non-alcoholic fatty liver disease in spondyloarthritis: identifying patients on therapy at high risk of serious liver disease

Stephanie R Harrison - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Nonalcoholic fatty liver disease

Methotrexate

Improving new patient appointment utilisation in rheumatology advanced practice physiotherapy

Sophie East - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Audit of bosentan use in Rapid Access to Digital Ulcer Clinic (RADUC) in systemic sclerosis: a single-centre experience

Marta Sobrado - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Pulmonary arterial hypertension

Bosentan

Quality Improvement Project: Improving Osteoporosis Treatment for Patients with a Neck of Femur Fracture

Gemma O'Hara - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

Musculoskeletal

Osteoporosis

Zolendronic acid

Successfully using video for DMARD and Biologic patient education

Rian Penford - British Society for Rheumatology (BSR) , 2023

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved